The U.S. Supreme Court’s 2013 ruling in Association for Molecular Pathology v. Myriad Genetics changed the landscape of what is considered patentable material in the context of genetic inventions. In the five years since Myriad, companies have pushed the boundaries of patenting certain types of genetic materials. Despite Myriad’s express statement that it was not considering “the patentability of DNA in which the order of the naturally occurring nucleotides has been altered,” the courts have not yet established the contours of how much nucleotide sequences need to be altered in order to “create something new” in order to be patentable. However, as we discuss in the next section, we expect the Court to address these questions as biotechnology companies increasingly invest resources into emerging, expensive technologies involving genes and seek to protect their investments through patents.
The post Post-Myriad Legal and Policy Considerations for Patenting Genetic Inventions appeared first on IPWatchdog.com | Patents & Patent Law.
- Doing it Their Way: Leaders Share Tips for Helping Women to Make it in the IP Game
- How Organizations Must Protect Themselves from Ransomware Attacks
- Using AI to Valuate and Determine Essentiality for SEPs
- Patent Procurement and Strategy for Business Success Part II: Claims – Targeting the Right Infringers
- Patent Procurement and Strategy for Business Success: Building and Strategically Using Patents that Target the Right Infringers and Thwart Competitive Countermeasures
- Patent Filings Roundup: Equitable IP Subsidiary Goes on Retail Shopping Spree; Fintiv ITC Denial Hits Roku Hard
- Drilling Down on Criticism of Top-Down Approach to Determining Essentiality
- The Biden Executive Order’s Restraint on Freedom of Contract: Regulation by Anecdote May Lead to Unintended Consequences
- IP Goes Pop! Ep #2: Intellectual Property Urban Legends – Taking on Myths About IP in Popular Culture
- Are 5% of All U.S. Issued Patents Presumed to Be Unenforceable Under Laches Due to Their Priority Claims?